Armata Gets $3.7M in Additional Funding From Defense Dept. for Bacterial Infection Treatment

By Kelly CloonanArmata Pharmaceuticals said it received an additional $3.7 million in non-dilutive funds from the Defense Department to continue developing a treatment for a type of bacterial infection.The biotechnology company said Wednesday it will use the funding for the Phase 3 clinical program…